{
    "clinical_study": {
        "@rank": "8405", 
        "arm_group": [
            {
                "arm_group_label": "ASP7991 group", 
                "arm_group_type": "Experimental", 
                "description": "receiving ASP7991 and Cinacalcet-placebo"
            }, 
            {
                "arm_group_label": "Cinacalcet group", 
                "arm_group_type": "Active Comparator", 
                "description": "receiving Cinacalcet and ASP7991-placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "To examine efficacy and safety after 12-week administration of ASP7991 in secondary\n      hyperparathyroidism patients undergoing hemodialysis"
        }, 
        "brief_title": "A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Secondary Hyperparathyroidism", 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a multicenter, double-blind, randomized, Cinacalcet hydrochloride-controlled,\n      parallel-group, dose-ascending study. Subjects judged to be eligible will be registered and\n      randomized into either ASP7991 group (receiving ASP7991 and cinacalcet-placebo) or\n      Cinacalcet group (receiving cinacalcet and ASP7991-placebo), and will receive 12-week (84\n      days) administration of study drug from first dialysis day in a week (treatment period), in\n      a double-blind manner. The dose of the study drugs will be increased every 3 weeks in\n      dose-ascending manner.\n\n      Follow-up assessment will be performed before starting first dialysis in a week, 1 week (7\n      days) after the completion of the treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are on stable chronic maintenance dialysis who are receiving\n             hemodialysis therapy 3 times/week since before 12-week (84 days) administration and\n             are also scheduled to undergo the regimen of 3 times/week hemodialysis during the\n             study period\n\n          -  Patients with secondary hyperparathyroidism\n\n          -  Patients whose serum iPTH concentration is >240 pg/mL and corrected serum Ca is \u2265 9.0\n             mg/dL\n\n          -  Patients who have had no changes in the following items \u22654-week (28 days).\n\n               -  Dosage and regimen, including new administration, of active vitamin D,\n                  calcitonin preparation, phosphate binder, and medication with phosphate\n                  absorption (including foods)\n\n               -  Ca concentration of the dialysate, membrane area of the dialyzer, and dialysis\n                  time of each week\n\n        Exclusion Criteria:\n\n          -  Patients who underwent parathyroid intervention, such as parathyroidectomy (PTx) or\n             percutaneous ethanol injection therapy (PEIT), within 24 weeks (168 days) prior to\n             the administration\n\n          -  Patients who have primary hyperparathyroidism\n\n          -  Patients who received bisphosphonate, estrogen preparation, parathyroid hormone\n             within 4 weeks (28 days)\n\n          -  Patients with uncontrolled hypertension (systolic blood pressure \u2265 180 mmHg and\n             diastolic blood pressure \u2265 120 mmHg are observed at >2/3 of all confirmable\n             measurements\n\n          -  Patients who are complicated by severe heart disorder [congestive cardiac failure\n             (NYHA classification III or higher), or wide range of old myocardial infarction], or\n             having a history of hospitalization for cerebro-vascular disease or heart disorder\n             within 12 weeks (84 days) before administration of the study drug\n\n          -  Patients with hepatic function abnormal (ALT or AST is >2\u00d7 ULN, or total bilirubin\n             (T-bil) is > 1.5 \u00d7 ULN.)\n\n          -  Patients with a history of malignant tumor or the patient's condition is complicated\n             by malignant tumor. (However, enrollment is acceptable if the tumor has not relapsed\n             for 5 years or longer.)\n\n          -  Patients with a history of serious drug allergy including anaphylactic shock\n\n          -  Patients with a history of drug allergy to Cinacalcet hydrochloride\n\n          -  Female patients who are potentially child-bearing or lactating, or patients who do\n             not comply with the instructed contraceptive measures\n\n          -  Patients who were or are currently involved in trials for other investigational drugs\n             or medical devices, or clinical trial for post-marketing study drugs within 12 weeks\n             (84 days) before the study\n\n          -  Patients who have received ASP7991 in the past\n\n          -  Patients who were judged ineligible to participate in the study by the investigator /\n             subinvestigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133404", 
            "org_study_id": "7991-CL-1004"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP7991 group", 
                "description": "oral", 
                "intervention_name": "ASP7991", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cinacalcet group", 
                "description": "oral", 
                "intervention_name": "Cinacalcet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ASP7991 group", 
                    "Cinacalcet group"
                ], 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "secondary hyperparathyroidism(SHPT)", 
            "Chronic kidney disease(CKD)", 
            "Mineral bone disease(MBD)"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tohoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of ASP7991 -A Double-blind, Cinacalcet Hydrochloride-controlled, Dose-ascending Study in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis -", 
        "overall_contact": {
            "email": "clinicaltrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "iPTH: intact parathyroid hormone", 
            "measure": "Serum iPTH concentration", 
            "safety_issue": "No", 
            "time_frame": "Before and at 8, 15, 22, 24, 29, 36, 43, 45, 50, 57, 64, 66, 71, 78, 85 and 92 days after start of the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ca x P will be calculated", 
                "measure": "Corrected serum Ca, Phosphate(P) concentration", 
                "safety_issue": "No", 
                "time_frame": "Before and at 3, 8, 15, 22, 24, 29, 36, 43, 45, 50, 57, 64, 66, 71, 78, 85 and 92 days after start of the treatment"
            }, 
            {
                "measure": "serum vitamin D concentration", 
                "safety_issue": "No", 
                "time_frame": "Before and at 22, 43, 64, 85 and 92 days after start of the treatment"
            }, 
            {
                "description": "wPTH: whole parathyroid hormone", 
                "measure": "serum wPTH concentration", 
                "safety_issue": "No", 
                "time_frame": "Before and at 22, 43, 64, 85 and 92 days after start of the treatment"
            }, 
            {
                "description": "Bone metabolism markers will be BAP (Bone specific alkaline phosphatase) and TRACP5b (Tartrate-resistant acid phosphatase-5b)", 
                "measure": "Serum concentration of bone metabolism markers", 
                "safety_issue": "No", 
                "time_frame": "Before and at 22, 43, 64, 85 and 92 days after start of the treatment"
            }, 
            {
                "measure": "Serum FGF23 concentration", 
                "safety_issue": "No", 
                "time_frame": "Before and at 22, 43, 64, 85 and 92 days after start of the treatment"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "For 12 weeks after start of treatment"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}